Physiologically Based Pharmacokinetic (PBPK) Modeling to Predict PET Image Quality of Three Generations EGFR TKI in Advanced-Stage NSCLC Patients.
Imke H BartelinkEveline Annette van de StadtA F LeeuwerikVictor L J L ThijssenJ R I HupselJ F van den NieuwendijkI BahceM YaqubN H HendriksePublished in: Pharmaceuticals (Basel, Switzerland) (2022)
The developed PBPK models adequately predicted the image quality of afatinib and osimertinib and erlotinib. Some deviations in predicted whole-body TBR lead to new hypotheses, such as increased affinity for mutated EGFR and active influx transport (erlotinib into excreting tissues) or active efflux (afatinib from brain), which is currently unaccounted for. In the future, PBPK models may be used to predict the image quality of new tracers.
Keyphrases
- image quality
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- computed tomography
- small cell lung cancer
- dual energy
- ejection fraction
- newly diagnosed
- end stage renal disease
- gene expression
- positron emission tomography
- prognostic factors
- magnetic resonance imaging
- resting state
- brain injury
- contrast enhanced
- white matter
- mass spectrometry
- subarachnoid hemorrhage
- cerebral ischemia
- pet imaging
- chronic myeloid leukemia